Core Viewpoint - Healthcare Triangle, Inc. has entered into a Sales Agreement with Spartan Capital Securities for an at-the-market offering program, allowing the company to raise up to $20 million through the sale of its common stock [1][2]. Group 1: Sales Agreement Details - The Sales Agreement was executed on November 18, 2025, enabling Healthcare Triangle to offer and sell shares with an aggregate market value of up to $20 million [2]. - Shares may be sold on the Nasdaq Capital Market or other trading venues at prevailing market prices, providing flexible access to capital for the company's operational and financial strategy [2]. Group 2: Company Focus and Support - Healthcare Triangle is focused on strengthening its platform and expanding capabilities in cloud-based healthcare solutions [3]. - Spartan Capital Securities expresses support for Healthcare Triangle through the ATM program, indicating a commitment to the company's capital markets initiatives [3]. Group 3: Regulatory Compliance - The shares offered under the ATM program will be issued pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-40903 HEALTHCARE TRIANGLE, INC. (Exact name of registrant as specified in its charter) | Delaware | 84-3559776 | | ...

PLEASANTON, CA / ACCESS Newswire / October 14, 2025 / The market always appreciates a great company story. The problem is that it often rewards the ones that sound big, not necessarily the ones that are big. ...

PLEASANTON, CA / ACCESS Newswire / October 13, 2025 / Healthcare Triangle Inc. (NASDAQ:HCTI) published a recent press release that included a headline that could've been mistaken for corporate filler- "executes aggressive growth." But this one hits different. ...

Core Insights - Healthcare Triangle, Inc. (HCTI) is experiencing significant momentum in the AI-powered healthcare technology sector, highlighted by two major developments that position the company for substantial revenue growth and recurring revenue streams [1][3][17] Group 1: Strategic Developments - HCTI signed a Letter of Intent to acquire Teyame.AI, which is expected to generate approximately $34 million in incremental annual revenue and $4.2 million in EBITDA [2][4][17] - The acquisition of Teyame.AI enhances HCTI's capabilities in AI-powered patient engagement, addressing the gap between advanced clinical systems and patient interaction [6][7][17] - HCTI's subsidiary QuantumNexis has processed over $20 million in revenue through its Ezovion platform, with projections to reach $37 million within six months, indicating an 85% increase [8][9][17] Group 2: Revenue Model Transformation - The upcoming launch of QuantumNexis's integrated payment gateway will create a scalable revenue stream by earning a percentage of all transactions processed through the platform [10][12][17] - This transformation positions HCTI as a hybrid SaaS + fintech company, allowing for recurring transaction-based revenue that scales with platform growth [11][12][17] Group 3: Financial Performance and Market Position - HCTI reported Q2 2025 revenues of $3.6 million, reflecting a 19% year-over-year growth, with a target of approximately $20 million for the full year [14][17] - The company has established strategic partnerships with major industry players such as Amazon AWS, Google Cloud, and Microsoft Azure, enhancing its distribution capabilities and validating its technology [15][17] - Recent contract wins with leading healthcare systems further demonstrate HCTI's market traction and growth potential [15][17] Group 4: Future Growth Pathways - The combination of the Teyame acquisition and QuantumNexis's revenue growth creates multiple expansion pathways for HCTI, appealing to diverse institutional investors [13][17][19] - The acquisition provides immediate access to high-growth international markets, including Europe, the Middle East, Asia-Pacific, and Latin America [17][19] - HCTI's technology integration with Teyame's AI capabilities enhances its existing platforms, creating powerful network effects and cross-selling opportunities [17][19]

PLEASANTON, CA / ACCESS Newswire / October 10, 2025 / Some companies tiptoe into innovation. Healthcare Triangle Inc. (NASDAQ: HCTI ) prefers to kick the door down. ...

Key Points - Several biotech stocks experienced notable after-hours gains on October 9, driven by new data and corporate developments [1] Company Summaries Palisade Bio Inc. (PALI) - Shares traded at $2.26 in after-hours, reflecting a 7.62% gain from the prior close of $2.10, which was up 5% on the day [1] - The company cancelled its special meeting of stockholders due to lack of quorum, withdrawing all proposals from consideration [2] Healthcare Triangle Inc. (HCTI) - Shares traded at $2.88 in after-hours, up 4.35% from the regular session close of $2.76, which was down 17.86% [3] - The company signed a non-binding Letter of Intent to acquire Teyame.AI, projected to generate $34 million in revenue for fiscal year 2025 [4] Nutriband Inc. (NTRB) - Shares traded at $8.25 in after-hours, up 4.30% from the regular session close of $7.91, which was down 6.94% [5] - The company filed a provisional patent application with the USPTO to strengthen its intellectual property for its AVERSA abuse deterrent transdermal [5] Karyopharm Therapeutics Inc. (KPTI) - Shares traded at $6.08 in after-hours, up 4.46% from the regular session close of $5.82, which had declined 1.36% [6] - The company announced financing transactions expected to provide $100 million in financial flexibility, extending its cash runway into Q2 2026 [6] Editas Medicine Inc. (EDIT) - Shares traded at $4.22 in after-hours, up 3.43% from the regular session close of $4.08, which was down 1.69% [7] - The company presented new preclinical proof-of-concept data for its therapy EDIT-401, showing a 90% LDL-C reduction in non-human primates and mice [7] CG Oncology Inc. (CGON) - Shares traded at $45.40 in after-hours, up 2.11% from the regular session close of $44.46, which gained 9.21% [8] - No official news releases or filings were issued during the day [8]

Core Points - Healthcare Triangle, Inc. (HCTI) has entered into warrant exercise agreements with accredited and institutional investors to exercise existing warrants for a total of 239,051 shares of common stock, generating approximately $478,000 in gross cash proceeds [1][2] - The existing warrants' exercise price has been reduced from $20.92 to $2.00 per share, and the new warrants will have an exercise price of $3.00 per share, with a five-year expiration from the date of issuance [1][2] Financial Details - The gross proceeds from the warrant inducement are expected to be around $478,000, excluding any potential proceeds from the exercise of the new warrants and before deducting financial advisor fees and other expenses [2] - The closing of the offering is anticipated to occur on or about October 8, 2025, subject to customary closing conditions [2]

Core Insights - WallachBeth Capital LLC announced that Healthcare Triangle, Inc. has entered into warrant exercise agreements with accredited and institutional investors [1] Company Summary - Healthcare Triangle, Inc. is recognized as a leader in digital transformation solutions for the healthcare and life sciences sectors [1] - The company has agreed to exercise outstanding warrants to purchase a total of 377,702 shares of its common stock [1]

Core Insights - Healthcare Triangle, Inc. has entered into warrant exercise agreements with three accredited investors to exercise existing warrants for a total of 812,775 shares of common stock, generating approximately $1.63 million in gross cash proceeds [1][2] - The existing warrants' exercise price has been reduced from $20.92 to $2.00 per share, and the new warrants will have an exercise price of $3.00 per share, with a total of 812,775 shares available for purchase [1] - The transaction is expected to close on October 2, 2025, subject to customary closing conditions [2] Financial Details - The gross proceeds from the warrant inducement are expected to be around $1.63 million, excluding potential proceeds from the exercise of the new warrants and before deducting placement agent fees and other expenses [2] - The new warrants will be exercisable upon stockholder approval and will expire five years from the date of such approval [1] Company Background - WallachBeth Capital LLC is acting as the sole placement agent for this warrant inducement transaction, providing capital markets and institutional execution services [2][4]